| Literature DB >> 19575798 |
Chien-Chang Huang1, Wun-Shaing Wayne Chang.
Abstract
BACKGROUND: Many mammalian genes are organized as bidirectional (head-to-head) gene pairs with the two genes separated only by less than 1 kb. The transcriptional regulation of these bidirectional gene pairs remains largely unclear, but a few studies have suggested that the two closely adjacent genes in divergent orientation can be co-regulated by a single transcription factor binding to a specific regulatory fragment. Here we report an evolutionarily conserved bidirectional gene pair, known as the PREPL-C2ORF34 gene pair, whose transcription relies on the synergic cooperation of two transcription factors binding to an intergenic bidirectional minimal promoter.Entities:
Mesh:
Substances:
Year: 2009 PMID: 19575798 PMCID: PMC2713978 DOI: 10.1186/1471-2199-10-67
Source DB: PubMed Journal: BMC Mol Biol ISSN: 1471-2199 Impact factor: 2.946
Figure 1Northern blot analysis of . Human 12 major tissue polyA+ RNA blot (OriGene) was hybridized with 32P-labeled PREPL (upper panel), C2ORF34 (middle panel) and control ACTB (β-actin; lower panel) cDNA probes. Note that the commercial ACTB probe can recognize non-muscle β-actin (upper band) as well as smaller size α- or γ-actin isoform (lower band) found in certain tissues such as heart and muscle.
Figure 2Determination of the size and sequence of the intergenic region between human . A) The first few exons of C2ORF34 (black boxes) and PREPL (grey boxes), the introns, and the shared intergenic segment (middle white bar) are shown. Bent arrows represent the gene directions and transcriptional start sites (TSSs) identified by 5'-RACE. The shortest intergenic distance between the two genes is calculated to be 405 bp and numbered (from -1 to -405) from the telomeric (tel) to the centromeric (cen) end. B) The 5'-RACE products, which were sequenced from the shared intergenic region to the direction of downstream gene transcription, revealed multiple TSSs (marked with an asterisk) including two for C2ORF34 and three for PREPL. C) The bent arrows and the bold C and G nucleotides denote the different TSSs for C2ORF34 and PREPL, respectively. The 405-bp intergenic region is boxed.
Figure 3Determination of the promoter activity of the intergenic region. The directions of gene transcription are indicated by arrows. Here, a 1053-bp fragment (from position -718 to +335) consisting of the entire 405-bp intergenic region and ~300 bp beyond its two boundaries is cloned as the full-length promoter construct. Progressive deletions from this full-length promoter construct were produced and inserted into the promoterless vector in either the sense (relative to PREPL) or antisense (relative to C2ORF34) direction. The resulting luciferase activity of transiently transfected U87MG cells is given adjacent to each construct. Co-transfection of pRL-TK plasmid was performed for normalization of transfection efficiencies and cell viability. Units are relative to SV40 control promoter, defined as 1×. The experiments were performed in triplicate. Data are representative of three independent experiments, and error bars are ± standard deviation. A similar result was also observed in human H4 cells (data not shown).
Figure 4Effect of promoter strength of the 243-bp regulatory element on the expressions of . A) Semi-quantitative RT-PCR analysis of C2ORF34, PREPL, and control ACTB transcripts. RNAs used in this analysis were obtained from human brain (H4 and U87MG) and lung (WI38 and IMR90) cells. The specific primers for each gene are indicated in the methods. B) The relative luciferase activities driven by the 243-bp (-445/-203) fragment toward either the C2ORF34 or PREPL direction in different cells were determined. The transfection efficiency and cell viability were normalized with the pRL-TK plasmid. Units are relative to the luciferase activity driven by the 243-bp bidirectional minimal promoter in C2ORF34 direction, defined as 100%. The experiments were performed in triplicate and repeated independently at least twice. The error bars are ± standard deviation.
Figure 5Multiple sequence alignment of the bidirectional minimal promoter region of the . The identified 243-bp bidirectional minimal promoter region on human chromosome 2p21 spans from the first 40-bp (position -445 to -406) of C2ORF34 exon 1 to the first half (position -405 to -203) of the intergenic region. All putative transcription factor binding sites found in this bidirectional promoter are indicated above the alignment. The core sequence of each transcription factor target site is highlighted in black, with the bent arrows representing two C2ORF34 TSSs.
Figure 6Identification of the functional significance of the NRF-2 and YY-1 binding sites in the bidirectional minimal promoter. Mutations at the first NRF-2 binding site are shown as a filled circle and denoted as -203/-445mu_NRF-2(A) in the antisense (relative to C2ORF34) and as -445/-203mu_NRF-2(A) in the sense (relative to PREPL) directions. Mutations at the second NRF-2 binding site are shown as a filled square and named as -203/-445mu_NRF-2(B) in the antisense and as -445/-203mu_NRF-2(B) in the sense directions. Mutations at the YY-1 binding site are shown as a filled triangle and termed as -203/-445mu_YY-1 and -445/-203mu_YY-1 in two different directions. Double mutations at both the NRF-2(B) and the YY-1 binding sites are denoted as -445/-203mu_NRF-2(B)/YY-1 and -203/-445mu_NRF-2(B)/YY-1. Units are relative to the wild-type bidirectional minimal promoter, defined as 100%. The experiments were performed in triplicate. Data are representative of three independent experiments, and error bars are ± standard deviation.
Figure 7Assessment of the effect of NRF-2 binding elements on the formation of protein/DNA complex. The EMSA analysis was conducted as described in the Methods section. The double-stranded oligonucleotide probe (-311/-282) encompassing both NRF-2(A) and NRF-2(B) binding sites is shown on top. The arrow indicates free probe, and the arrowheads indicate three shifted bands found in the bottom panel. Lane 1 represents the biotin-labeled probe alone. Lane 2 represents the hot probe incubated with nuclear extracts. Lanes 3 and 4 represent the hot probe incubated with nuclear extracts in the presence of either 1- or 10-fold molar excess of cold wild-type probe, respectively. Lanes 5 and 6 represent the hot probe incubated with nuclear extracts in the presence of either 1- or 10-fold molar excess of unlabelled probe with mutation at the NRF-2(B) site, respectively. Lanes 7 and 8 are the same as lanes 5 and 6 except a cold probe with mutation at the NRF-2(A) site was used.
Figure 8Identification of NRF-2 and YY-1 binding specificities to the bidirectional minimal promoter. The probe (-311/-282) which includes NRF-2 binding sites and the probe (-290/-204) which contains the sole YY-1 binding site are shown on top. Lanes 1 and 7 represent each probe incubated with nuclear extracts alone. Lanes 2 and 8 represent each probe incubated with a 1-fold molar excess of the cold competitor oligonucleotide. Lanes 3 and 9 represent each probe competed with a 10-fold molar excess of the unlabeled competitor oligonucleotide. Lanes 4 to 6 and 10 to 12 represent the same EMSA performed in the presence of three different antibodies: anti-NRF-2, anti-YY-1, and the negative control, anti-NF-1 antibody. The experiments were repeated twice.
Figure 9Semi-quantitative PCR products from DNA prepared by ChIP assays. Lanes 1 and 5: No DNA control. Lanes 2 and 6: The Input lanes correspond to PCR products derived from a 1/10 dilution of chromatin prior to immunoprecipitation. Lanes 3 and 7: The IgG lanes correspond to PCRs containing chromatin immunoprecipitated with antibodies against control IgG. Lanes 4 and 8: The NRF-2α and YY-1 lanes correspond to PCRs containing chromatin immunoprecipitated with antibodies against NRF-2α and YY-1, respectively. All the amplified products represent a 254-bp region (from position -66 to -319) containing both the NRF-2 and YY-1 binding sites of the PREPL-C2ORF34 bidirectional gene pair. Additional ChIP assays were performed in other cell lines with similar results (presented in Additional File 4).
List of primers used to amplify the PREPL-C2ORF34 bidirectional promoter fragments
| +335/-718 | 5'-GAAGATCTGAATGCAACAGGGAG-3' | 5'-GAAGCTTCGCAGGTGGCTCCCGG-3' |
| -11/-718 | 5'-AGATCTAGCACGAGCAACAGGCAGAT-3' | 5'-GAAGCTTCGCAGGTGGCTCCCGG-3' |
| -203/-718 | 5'-AGATCTGGTCCGCCCTCACTCAAGAT-3' | 5'-GAAGCTTCGCAGGTGGCTCCCGG-3' |
| -420/-718 | 5'-AGATCTCGGGTGTGGAAGGCTCCAGTGAGAT-3' | 5'-GAAGCTTCGCAGGTGGCTCCCGG-3' |
| -580/-718 | 5'-AGATCTGGTAAGGGAGAACCTGCTCG-3' | 5'-GAAGCTTCGCAGGTGGCTCCCGG-3' |
| -203/-445 | 5'-AGATCTGGTCCGCCCTCACTCAAGAT-3' | 5'-AAGCTTATCTCACTGGAGCCTTCCACACCCG-3' |
| -262/-445 | 5'-AGATCTTCGGCCCTGGTTGCCAAGGAGAT-3' | 5'-AAGCTTATCTCACTGGAGCCTTCCACACCCG-3' |
| -203/-385 | 5'-AGATCTGGTCCGCCCTCACTCAAGAT-3' | 5'-AAGCTTCCTGCCAACTTCTTCCCTGT-3' |
| -203/-345 | 5'-AGATCTGGTCCGCCCTCACTCAAGAT-3' | 5'-AAGCTTACCCTCCCTCCACCGGACCA-3' |
| -718/+335 | 5'-AGATCTTCGCAGGTGGCTCCCGGC-3' | 5'-AAGCTTGATCTGAATGCAACAGGGAG-3' |
| -600/+335 | 5'-AGATCTCGAGCAGGTTCTCCCTTACC-3' | 5'-AAGCTTGATCTGAATGCAACAGGGAG-3' |
| -445/+335 | 5'-AGATCTCACTGGAGCCTTCCACACCCG-3' | 5'-AAGCTTGATCTGAATGCAACAGGGAG-3' |
| -225/+335 | 5'-AGATCTTGAGTGAGGGCGGACCAGA-3' | 5'-AAGCTTGATCTGAATGCAACAGGGAG-3' |
| -33/+335 | 5'-AGATCTGCCTGTTGCTCGTGCTAGA-3' | 5'-AAGCTTGATCTGAATGCAACAGGGAG-3' |
| -445/-203 | 5'-GAAAGATCTCACTGGAGCCTTCCACACCCG-3' | 5'-AAGCTTCTGGTCCGCCCTCACTCAAGAT-3' |
| -445/-262 | 5'-GAAAGATCTCACTGGAGCCTTCCACACCCG-3' | 5'-AAGCTTCGGCCCTGGTTGCCAAGGAGAT-3' |
| -385/-203 | 5'-AGATCTCCTGCCAACTTCTTCCCTGT-3' | 5'-AAGCTTCTGGTCCGCCCTCACTCAAGAT-3' |
| -345/-203 | 5'-AGATCTACCCTCCCTCCACCGGACCA-3 | 5'-AAGCTTCTGGTCCGCCCTCACTCAAGAT-3' |
*All construct names refer to the positions of nucleotides, counting from the first to the last nucleotide of the inserted genomic DNA sequences. The inserted fragments were first amplified by PCR using a series of forward primers with a BglII site (5'-AGATCT) and reversed primers with a HindIII site (5'-AAGCTT). Each amplified fragment was then digested with two restriction enzymes and cloned into the pGL3-Basic vector (Promega).